SVRA Stock — Savara Inc.: Cash, EV, Pipeline

Share price

$5.37

Market cap

$1,103.3M

Cash

$173.0M

Enterprise value

$960.4M

Balance sheet

Cash	$173.0M
Debt	$30.1M
Net cash	$142.9M
Enterprise value	$960.4M
Basic shares	205.4M shares
Fully diluted shares	239.8M shares
Fully diluted market cap	$1,287.8M
Cash per share	$0.84

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SVRA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	Molgramostim	Phase 3	Autoimmune Pulmonary Alveolar Proteinosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Molgramostim inhalation solution

Phase 3 · Active Modality: inhaled biologic

Aliases MOLBREEVI

Target GM-CSF (granulocyte-macrophage colony-stimulating factor)

Partnerships RTW Investments: $75M royalty purchase payable on FDA approval by Mar 31, 2027 (royalties 1.0-9.5% of US net sales, capped at $187.5M).

Indications

Autoimmune pulmonary alveolar proteinosis (autoimmune PAP) (Phase 3)

Status note Company's sole program; inhaled GM-CSF in Phase 3 development for autoimmune PAP. No product revenue; not yet commercial.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Molgramostim
Lead indication	Autoimmune Pulmonary Alveolar Proteinosis
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06431776	Phase 3	Recruiting	Sponsor	SVRA	—	Autoimmune Pulmonary Alveolar Proteinosis	—
NCT04544293	Phase 3	Active, not recruiting	Sponsor	SVRA	—	Autoimmune Pulmonary Alveolar Proteinosis	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Savara Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	9,720,852	no change	1.30%	2026-08-14
RTW Investments	5,952,380	no change	0.31%	2026-08-14
OrbiMed Advisors	3,959,900	+3,324,900	0.46%	2026-08-14
ADAR1 Capital Management	1,403,409	-61,126	0.41%	2026-08-14
Sphera Biotech	756,164	+17,000	0.67%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SVRA — Savara Inc.